NeuBase Therapeutics with ticker code (NBSE) now have 6 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 18 and 13 and has a mean target at 15.67. Now with the previous closing price of 8.14 this now indicates there is a potential upside of 92.5%. The day 50 moving average is 8.06 and the 200 day MA is 8.32. The market capitalisation for the company is $180m. Company Website: http://www.neubasetherapeutics.com
NeuBase Therapeutics, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics is headquartered in Pittsburgh, Pennsylvania.
